Incumaker announces acquisition of CEN Biotech, Inc. by subsidiary, Eastern Starr Biotech, Inc.

ATLANTA, April 12, 2017 -- Incumaker, Inc. (OTC Pink:QMKR) announced today that its wholly owned subsidiary, Eastern Starr Biotech, Inc., has acquired CEN Biotech, Inc..

CEN Biotech, Inc. (“CEN”) and its global ventures will continue to live on through a new entity,  Eastern Starr Biotech Inc. (“Eastern Starr, Inc.”).   At its helm will be Joseph Byrne, as its Chief Executive Officer.

Specifically, CEN has entered into a forward triangular merger with Eastern Starr the wholly owned subsidiary of Incumaker, Inc. created specifically for the purpose of acquiring CEN Biotech, Inc. and accomplished as a stock for stock transaction pursuant to IRS Code Section 368(a)(2)(D).   Incumaker, Inc. is a publicly traded company trading on the OTC markets.  Eastern Starr will continue CEN’s business purpose seeking to expand it further into the global market.

As consideration (compensation) for the acquisition of CEN, Incumaker shall transfer 100,000,000 shares of its voting common stock, which will be disbursed amongst CEN shareholders on a proportionate basis.  Eastern Starr Biotech, Inc. will acquire all of the assets of CEN, including Tesla Digital and its patents, and all of its stock which shall be retired.  This merger is in the best interests of both entities and its shareholders, and the executives at Incumaker will continue to lend valuable insight into the future. 

About CEN Biotech, Inc.

CEN Biotech is an early stage Canadian biopharmaceutical company founded to integrate agronomical and pharmaceutical principles for the purposes of growing, selling, processing and delivering pharmaceutical-grade medical marijuana in its pure and extracted form to patients in accordance with Health Canada’s newly-formed Marihuana for Medical Purposes Regulations (MMPR). 

CEN had been actively pursuing business opportunities globally with the intent to grow, sell, process and deliver pharmaceutical grade medical marijuana in various drug delivery mechanisms within nations where it is legal.   CEN has also been pursuing an entry into the hemp production industry.

About Incumaker

Incumaker, Inc. (OTC Pink:QMKR) is a diversified holding company whose strategic plan is to acquire interests in young businesses, and provide financing, advice and guidance to assist them in realizing their potential. The company’s wholly owned subsidiary, Eastern Starr Biotech, is pursuing strategic acquisitions in the Cannabis industries.  We continue to identify and evaluate other potential acquisitions that we believe will create shareholder value and return. Additional information will be available in the 8k to be filed at www.sec.gov.  For additional information please email [email protected].

Press Releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project," "propose," "plan," "intend," and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company.